Early Hepatitis C Trial Data Shows INX-189 to Be Effective
Inhibitex Reports Positive Data From Ongoing Phase 1b Clinical Trial Of INX-189
(RTTNews) – Inhibitex, Inc. (INHX: News ) reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus or HCV.
The company added that the trial, which is being conducted under an IND in the United States, is a double-blind, placebo-controlled, dose escalation study, administered orally once-daily for seven days, for the treatment of HCV genotype 1 treatment naïve patients. Each treatment cohort in the study is comprised of 10 patients, eight that receive INX-189 and two that receive placebo.
Continue reading this entire article: